Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

579

Figures (1-6)

154

Tables (1-13)

152

Sum=920

Publishing Process of This Article

Item

Count

Browse

Download

Sum=77

May 26, 2025 (publication date) through Jun 28, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Stem Cells. May 26, 2025; 17(5): 101675
Published online May 26, 2025. doi: 10.4252/wjsc.v17.i5.101675

Table 12 Results of the Wilcoxon signed-rank test for changes in the Qualiveen Short Form values before and after intervention

SFQ: Qualiveen Short Form.

Citation: Kaplan N, Kabatas S, Civelek E, Savrunlu EC, Akkoc T, Boyalı O, Öztürk E, Can H, Genc A, Karaöz E. Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study. World J Stem Cells 2025; 17(5): 101675
URL: https://www.wjgnet.com/1948-0210/full/v17/i5/101675.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i5.101675